Regulation of Alzheimer's Disease by Chinese Medicine Based on BDNF/TrkB Signaling Pathway： A Review
10.13422/j.cnki.syfjx.20240719
- VernacularTitle:基于BDNF/TrkB信号通路探讨中药调控阿尔茨海默病的研究进展
- Author:
Liuping YUE
1
;
Yongkang SUN
1
;
Fangbiao XU
1
;
Yanbo SONG
1
;
Xinzhi WANG
1
Author Information
1. Encephalopathy Center of The First Affiliated Hospital of Henan University of Chinese Medicine， Zhengzhou 450046， China
- Publication Type:Journal Article
- Keywords:
Alzheimer's disease;
Chinese medicine;
Chinese medicine compounds;
brain-derived neurotrophic factor （BDNF）/tropomyosin receptor kinase （TrkB） signaling pathway;
review
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(20):274-282
- CountryChina
- Language:Chinese
-
Abstract:
Alzheimer's disease （AD） is a chronic neurodegenerative disorder characterized by the progressive loss of cognitive and memory functions. Its pathological features mainly include neurofibrillary tangles formed by the aggregation of hyperphosphorylated tau proteins and amyloid plaques formed by the accumulation of β-amyloid. The exact pathogenesis of AD has not been fully elucidated， and there are currently no effective specific drugs or radical treatments available in clinical practice. In recent years， the incidence of AD has been on the rise， severely affecting life and health， making the search for effective drugs and therapeutic components for AD treatment crucial. Modern medical research has found that the brain-derived neurotrophic factor （BDNF）/tropomyosin receptor kinase B （TrkB） signaling pathway is closely related to neurogenesis， apoptosis， neuroinflammation， synaptic plasticity， and oxidative stress， playing a vital role in the pathophysiological development of AD. Additionally， Chinese medicine has a long history of treating neurodegenerative diseases with few adverse reactions and features a multi-target， multi-link， and multi-pathway approach to treatment. Therefore， the author reviewed the latest research reports in China and abroad to elaborate on the role of the BDNF/TrkB signaling pathway in the onset and progression of AD， and summarized the research progress on the regulation of the BDNF/TrkB pathway by Chinese medicine compounds and monomers in AD intervention. This study is expected to provide references for the development of clinical drugs for the prevention and treatment of AD and to broaden the perspective on Chinese medicine treatment of AD.
